This page shows the latest blood diseases news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company working to drive change to defeat diabetes and other serious chronic diseases such as obesity and ... rare blood and endocrine disorders by pioneering
developing medicines for malignant and non-malignant blood diseases for more than 20 years. ... For 20 years, we have remained committed to deepening our understanding of many benign and malignant blood disorders in order to better meet the urgent needs
investment in immunological/inflammatory diseases, rare blood disorders, cancer and vaccines as well as digital healthcare.
SAR442168 – a BTK inhibitor licensed from Principia Biopharma that can cross the blood brain barrier – significantly reduced disease activity associated with MS measured using magnetic resonance imaging (MRI) in the phase ... its investment in
He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to ... atopic dermatitis and asthma therapy Dupixent (dupilumab) and
immunotherapy. Kiadis has focused its energies to date on the development of T cell-based therapies that are intended to support patients undergoing haematopoietic stem cell transplants (HSCT) to treat diseases ... Adding CytoSen gives it a second
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
The message? Bad Blood isn’t just a Taylor Swift anthem, it’s the root cause of life-limiting diseases – liquid cancers and non-malignant blood disorders – that haven’t traditionally ... That’s understandable; the prevalence of major cancers
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been ... Meanwhile, Galapagos looks set to continue adding to its
Our own cells will also be able to treat and cure diseases and conditions of the blood and immune system, as well as restore the blood system after treatments for specific ... Regenerative medicine is poised to transform healthcare as we know it,
The US biotech company aims to have four groundbreaking gene therapies launched by 2022 – with the promise of lives transformed in each of these rare blood diseases – and realistic hope of ... Interim trial data showed the therapy can reduce by 30-60%
Sanofi was also interested in caplacizumab, which fits not only with its rare disease focus but also enhances its portfolio of products for rare blood diseases coming from its acquisition of ... The company has a focus in neurodegenerative diseases and a
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic ... diseases.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...